利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.019 秒)

    Modified Hepatitis C virus proteins
    4.
    发明授权
    Modified Hepatitis C virus proteins 有权
    改良丙型肝炎病毒蛋白

    公开(公告)号：US09079950B2

    公开(公告)日：2015-07-14

    申请号：US13813929

    申请日：2011-08-04

    申请人： Heidi Drummer ,  Kathleen McCaffrey ,  Pantelis Poumbourios

    发明人： Heidi Drummer ,  Kathleen McCaffrey ,  Pantelis Poumbourios

    IPC分类号： C07K14/18 ,  G01N33/569 ,  A61K39/12 ,  C07K16/10 ,  C12N7/00 ,  C07K14/005

    CPC分类号： C07K14/1833 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C07K16/109 ,  C07K2317/76 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24261 ,  C12N2770/24262 ,  G01N33/56983

    摘要： A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof. A method of producing a composition comprising at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70% monomelic HCV E2 polypeptide, the method comprising expressing a polypeptide in a host cell and isolating the expressed product, wherein the polypeptide is an HCV E2 polypeptide including a receptor binding variant, and wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597.

    摘要翻译： 一种组合物，其包含包含受体结合变体的丙型肝炎病毒（HCV）包膜2（E2）多肽，其中所述多肽被修饰为包含：（i）在2,3或4个半胱氨酸突变或破坏的半胱氨酸，所述半胱氨酸选自C452， C486，C569和C597; 并且其中所述多肽通过分子间二硫键相对于没有半胱氨酸修饰的HCV E2多肽而形成基本上更少的多聚体，并且基本上保留CD81结合; 及其各种用途。 一种制备包含至少40％，或至少45％，或至少50％，或至少55％，或至少60％，或至少65％，或至少70％单体HCV E2的组合物的方法 所述方法包括在宿主细胞中表达多肽并分离所述表达的产物，其中所述多肽是包含受体结合变体的HCV E2多肽，并且其中所述多肽被修饰为包含：（i）半胱氨酸被突变或破坏在 2,3或4个选自C452，C486，C569和C597的半胱氨酸。

    MODIFIED HEPATITIS C VIRUS PROTEINS
    7.
    发明申请
    MODIFIED HEPATITIS C VIRUS PROTEINS 有权
    改良型HEPATITIS C病毒蛋白

    公开(公告)号：US20130224246A1

    公开(公告)日：2013-08-29

    申请号：US13813929

    申请日：2011-08-04

    申请人： Heidi Drummer ,  Kathleen McCaffrey ,  Pantelis Poumbourios

    发明人： Heidi Drummer ,  Kathleen McCaffrey ,  Pantelis Poumbourios

    IPC分类号： C07K14/18 ,  G01N33/569

    CPC分类号： C07K14/1833 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C07K16/109 ,  C07K2317/76 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24261 ,  C12N2770/24262 ,  G01N33/56983

    摘要： A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof. A method of producing a composition comprising at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70% monomelic HCV E2 polypeptide, the method comprising expressing a polypeptide in a host cell and isolating the expressed product, wherein the polypeptide is an HCV E2 polypeptide including a receptor binding variant, and wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597.

    摘要翻译： 一种组合物，其包含包含受体结合变体的丙型肝炎病毒（HCV）包膜2（E2）多肽，其中所述多肽被修饰为包含：（i）在2,3或4个半胱氨酸突变或破坏的半胱氨酸，所述半胱氨酸选自C452， C486，C569和C597; 并且其中所述多肽通过分子间二硫键相对于没有半胱氨酸修饰的HCV E2多肽而形成基本上更少的多聚体，并且基本上保留CD81结合; 及其各种用途。 一种制备包含至少40％，或至少45％，或至少50％，或至少55％，或至少60％，或至少65％，或至少70％单体HCV E2的组合物的方法 所述方法包括在宿主细胞中表达多肽并分离所述表达的产物，其中所述多肽是包含受体结合变体的HCV E2多肽，并且其中所述多肽被修饰为包含：（i）半胱氨酸被突变或破坏在 2,3或4个选自C452，C486，C569和C597的半胱氨酸。

    Heat treatment of a non-A, non-B hepatitis agent to prepare a vaccine
    9.
    发明授权
    Heat treatment of a non-A, non-B hepatitis agent to prepare a vaccine 失效
    非A非乙型肝炎药物的热处理制备疫苗

    公开(公告)号：US4438098A

    公开(公告)日：1984-03-20

    申请号：US343026

    申请日：1982-01-27

    申请人： Edward Tabor ,  Robert J. Gerety

    发明人： Edward Tabor ,  Robert J. Gerety

    IPC分类号： A61K39/29 ,  C12N7/04

    CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/5252 ,  C12N2770/24234 ,  C12N2770/24261

    摘要： A method of treating the agent of human non-A, non-B hepatitis to render it incapable of causing infection which comprises heating said agent at about 60.degree. C. for about 10 hours and recovering the treated protective agent. Furthermore, this treated agent may be utilized as a vaccine, as, for example, inoculating chimpanzees by i.v. inoculation with the heat treated non-A, non-B agent and the animals have been found protected from later challenge by non-A, non-B hepatitis agent. Thus, the second part of the invention resides in the utilization of a heat-treated agent from human plasma later utilized to protect chimpanzees by incoluation and utilization as a vaccine.

    摘要翻译： 一种治疗人非A非乙型肝炎药物的方法，使其不能引起感染，其包括在约60℃下加热所述试剂约10小时并回收经处理的保护剂。 此外，该处理剂可以用作疫苗，例如用i.v.接种黑猩猩。 已经发现用热处理的非A，非B剂和动物接种非保护性非乙型肝炎药物免于后续攻击。 因此，本发明的第二部分在于利用来自人血浆的热处理剂以后用于通过作为疫苗的缓释和利用来保护黑猩猩。